Stay updated with breaking news from Nuclear Export. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) EVP Reshma Rangwala sold 6,770 shares of the business’s stock in a transaction on Thursday, April 20th. The shares were sold at an average price of $4.05, for a total transaction of $27,418.50. Following the transaction, the executive vice president now directly owns 158,230 shares of the company’s […]
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) saw a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 19,090,000 shares, a growth of 14.1% from the March 15th total of 16,730,000 shares. Based on an average daily trading volume, of 2,600,000 shares, the days-to-cover ratio […]
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) – Equities researchers at Wedbush lifted their Q1 2023 earnings per share (EPS) estimates for shares of Karyopharm Therapeutics in a research note issued on Wednesday, April 19th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($0.34) for the quarter, up […]
Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) have been assigned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The […]
– At Week 24, 60mg of Selinexor in Combination with Ruxolitinib Achieved: 92% SVR35 and 78% TSS50 in Efficacy Evaluable Population, 79% SVR35 and 58% TSS50 in...